Estrogen inhibits cell cycle progression and retinoblastoma phosphorylation in rhesus ovarian surface epithelial cell culture

Jay W. Wright, Richard Stouffer, Karin D. Rodland

    Research output: Contribution to journalArticle

    11 Citations (Scopus)

    Abstract

    Estrogen promotes the growth of some ovarian cancer cells at nanomolar concentrations, but has been shown to inhibit growth of normal ovarian surface epithelial (OSE) cells at micromolar concentrations (1μg/ml). OSE cells express the estrogen receptor (ER)-α, and are the source of 90% of ovarian cancers. The potential sensitivity of OSE cells to estrogen stresses the importance of understanding the estrogen-dependent mechanisms at play in OSE proliferation and transformation, as well as in anticancer treatment. We investigated the effects of estradiol on cell proliferation in vitro, and demonstrate an intracellular locus of action of estradiol in cultured rhesus ovarian surface epithelial (RhOSE) cells. We show that ovarian and breast cells are growth-inhibited by micromolar concentrations of estradiol, and that this inhibition correlates with estrogen receptor expression. We further show that normal rhesus OSE cells do not activate ERK or Akt in response to estradiol, nor does estradiol block the ability of serum to stimulate ERK or induce cyclin D expression. Contrarily, estradiol inhibits serum-dependent retinoblastoma protein (Rb) phosphorylation and blocks DNA synthesis. This inhibition does not formally arrest cells, and is reversible within hours of estrogen withdrawal. Our data are consistent with growth inhibition by activation of Rb and indicate that sensitivity to hormone therapy in anticancer treatment can be modulated by cell cycle regulators downstream of the estrogen receptor.

    Original languageEnglish (US)
    Pages (from-to)1-10
    Number of pages10
    JournalMolecular and Cellular Endocrinology
    Volume208
    Issue number1-2
    DOIs
    StatePublished - Oct 31 2003

    Fingerprint

    Phosphorylation
    Retinoblastoma
    Cell culture
    Estradiol
    Cell Cycle
    Estrogens
    Cell Culture Techniques
    Epithelial Cells
    Cells
    Estrogen Receptors
    Growth
    Ovarian Neoplasms
    Cyclin D
    Retinoblastoma Protein
    Cell proliferation
    Cell growth
    Serum
    Breast
    Chemical activation
    Cell Proliferation

    Keywords

    • Antiestrogen
    • ERK
    • Estrogen
    • OSE
    • Proliferation
    • Rb

    ASJC Scopus subject areas

    • Endocrinology
    • Endocrinology, Diabetes and Metabolism

    Cite this

    Estrogen inhibits cell cycle progression and retinoblastoma phosphorylation in rhesus ovarian surface epithelial cell culture. / Wright, Jay W.; Stouffer, Richard; Rodland, Karin D.

    In: Molecular and Cellular Endocrinology, Vol. 208, No. 1-2, 31.10.2003, p. 1-10.

    Research output: Contribution to journalArticle

    @article{4b9143e859a64c679580f9032e4a595c,
    title = "Estrogen inhibits cell cycle progression and retinoblastoma phosphorylation in rhesus ovarian surface epithelial cell culture",
    abstract = "Estrogen promotes the growth of some ovarian cancer cells at nanomolar concentrations, but has been shown to inhibit growth of normal ovarian surface epithelial (OSE) cells at micromolar concentrations (1μg/ml). OSE cells express the estrogen receptor (ER)-α, and are the source of 90{\%} of ovarian cancers. The potential sensitivity of OSE cells to estrogen stresses the importance of understanding the estrogen-dependent mechanisms at play in OSE proliferation and transformation, as well as in anticancer treatment. We investigated the effects of estradiol on cell proliferation in vitro, and demonstrate an intracellular locus of action of estradiol in cultured rhesus ovarian surface epithelial (RhOSE) cells. We show that ovarian and breast cells are growth-inhibited by micromolar concentrations of estradiol, and that this inhibition correlates with estrogen receptor expression. We further show that normal rhesus OSE cells do not activate ERK or Akt in response to estradiol, nor does estradiol block the ability of serum to stimulate ERK or induce cyclin D expression. Contrarily, estradiol inhibits serum-dependent retinoblastoma protein (Rb) phosphorylation and blocks DNA synthesis. This inhibition does not formally arrest cells, and is reversible within hours of estrogen withdrawal. Our data are consistent with growth inhibition by activation of Rb and indicate that sensitivity to hormone therapy in anticancer treatment can be modulated by cell cycle regulators downstream of the estrogen receptor.",
    keywords = "Antiestrogen, ERK, Estrogen, OSE, Proliferation, Rb",
    author = "Wright, {Jay W.} and Richard Stouffer and Rodland, {Karin D.}",
    year = "2003",
    month = "10",
    day = "31",
    doi = "10.1016/j.mce.2003.08.001",
    language = "English (US)",
    volume = "208",
    pages = "1--10",
    journal = "Molecular and Cellular Endocrinology",
    issn = "0303-7207",
    publisher = "Elsevier Ireland Ltd",
    number = "1-2",

    }

    TY - JOUR

    T1 - Estrogen inhibits cell cycle progression and retinoblastoma phosphorylation in rhesus ovarian surface epithelial cell culture

    AU - Wright, Jay W.

    AU - Stouffer, Richard

    AU - Rodland, Karin D.

    PY - 2003/10/31

    Y1 - 2003/10/31

    N2 - Estrogen promotes the growth of some ovarian cancer cells at nanomolar concentrations, but has been shown to inhibit growth of normal ovarian surface epithelial (OSE) cells at micromolar concentrations (1μg/ml). OSE cells express the estrogen receptor (ER)-α, and are the source of 90% of ovarian cancers. The potential sensitivity of OSE cells to estrogen stresses the importance of understanding the estrogen-dependent mechanisms at play in OSE proliferation and transformation, as well as in anticancer treatment. We investigated the effects of estradiol on cell proliferation in vitro, and demonstrate an intracellular locus of action of estradiol in cultured rhesus ovarian surface epithelial (RhOSE) cells. We show that ovarian and breast cells are growth-inhibited by micromolar concentrations of estradiol, and that this inhibition correlates with estrogen receptor expression. We further show that normal rhesus OSE cells do not activate ERK or Akt in response to estradiol, nor does estradiol block the ability of serum to stimulate ERK or induce cyclin D expression. Contrarily, estradiol inhibits serum-dependent retinoblastoma protein (Rb) phosphorylation and blocks DNA synthesis. This inhibition does not formally arrest cells, and is reversible within hours of estrogen withdrawal. Our data are consistent with growth inhibition by activation of Rb and indicate that sensitivity to hormone therapy in anticancer treatment can be modulated by cell cycle regulators downstream of the estrogen receptor.

    AB - Estrogen promotes the growth of some ovarian cancer cells at nanomolar concentrations, but has been shown to inhibit growth of normal ovarian surface epithelial (OSE) cells at micromolar concentrations (1μg/ml). OSE cells express the estrogen receptor (ER)-α, and are the source of 90% of ovarian cancers. The potential sensitivity of OSE cells to estrogen stresses the importance of understanding the estrogen-dependent mechanisms at play in OSE proliferation and transformation, as well as in anticancer treatment. We investigated the effects of estradiol on cell proliferation in vitro, and demonstrate an intracellular locus of action of estradiol in cultured rhesus ovarian surface epithelial (RhOSE) cells. We show that ovarian and breast cells are growth-inhibited by micromolar concentrations of estradiol, and that this inhibition correlates with estrogen receptor expression. We further show that normal rhesus OSE cells do not activate ERK or Akt in response to estradiol, nor does estradiol block the ability of serum to stimulate ERK or induce cyclin D expression. Contrarily, estradiol inhibits serum-dependent retinoblastoma protein (Rb) phosphorylation and blocks DNA synthesis. This inhibition does not formally arrest cells, and is reversible within hours of estrogen withdrawal. Our data are consistent with growth inhibition by activation of Rb and indicate that sensitivity to hormone therapy in anticancer treatment can be modulated by cell cycle regulators downstream of the estrogen receptor.

    KW - Antiestrogen

    KW - ERK

    KW - Estrogen

    KW - OSE

    KW - Proliferation

    KW - Rb

    UR - http://www.scopus.com/inward/record.url?scp=0142168948&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0142168948&partnerID=8YFLogxK

    U2 - 10.1016/j.mce.2003.08.001

    DO - 10.1016/j.mce.2003.08.001

    M3 - Article

    C2 - 14580716

    AN - SCOPUS:0142168948

    VL - 208

    SP - 1

    EP - 10

    JO - Molecular and Cellular Endocrinology

    JF - Molecular and Cellular Endocrinology

    SN - 0303-7207

    IS - 1-2

    ER -